glp-1 for obesity monroe World Health Organization issues first-ever guidelines use of weight loss medications GLP-1 Injections for Medical Weight

A final determination is expected later in 2026

DJD, together with the Toronto General Hospital and the University of Toronto, has licensed patents supporting the development of DPP-4 inhibitors for type 2 diabetes and GLP-2 receptor agonists for short bowel syndrome

Studies are exploring its potential to slow the progression of neurodegenerative diseases like Parkinsons and Alzheimers, possibly by reducing inflammation and improving neuronal function

June 5, 2025 11:19 View More The Missing Link in Thyroid Healing Adrenal Truths with McCall McPherson In this podcast episode, McCall McPherson explores the crucial connection between adrenal function and thyroid conditions

A recent nationwide estimate of obesity indicated that 42% of adults aged 20 and over are obese

Hypoglycaemia risk increases when GLP-1 agonists are combined with insulin or sulphonylureas, requiring careful medication review and dose adjustment